#ACROSS2 - Twitter Hashtag

9 months ago

2. #ACROSS2: 1L, Aumolertinib + Chemo vs. Aumolertinib in common EGFR+ & Tumor suppressor genes in metastatic NSCLC: - ORR 70.4% vs 67.2% - mPFS 19.8mos vs 16.5mos (HR: 0.55) - OS immature - Most AEs were Gr1/2 3/6

OncBrothers's tweet photo. 2. #ACROSS2: 1L, Aumolertinib + Chemo vs. Aumolertinib in common EGFR+ & Tumor suppressor genes in metastatic NSCLC:

- ORR 70.4% vs 67.2%
- mPFS 19.8mos vs 16.5mos (HR: 0.55)
- OS immature
- Most AEs were Gr1/2

3/6 https://t.co/enLYDE3brq

Hidehito HORINOUCHI

@HHorinouchi

9 months ago

☑️#WCLC25 #LCSM Presidential🆙 🔥ACROSS Aumolertinib + Chemo in EGFRm 🎯PFS HR 0.55 (0.34-0.91) 🎙️ Dr. Jie Wang @OncoAlert @Larvol @IASLC https://t.co/YJWxTOHS12

HHorinouchi's tweet photo. ☑️#WCLC25 #LCSM Presidential🆙
🔥ACROSS Aumolertinib + Chemo in EGFRm
🎯PFS HR 0.55 (0.34-0.91)
🎙️ Dr. Jie Wang
@OncoAlert @Larvol @IASLC
https://t.co/YJWxTOHS12 https://t.co/otmg50GI2o

0

13

5

1

6K

1

2

0

1K

Oncology Brothers

@OncBrothers

9 months ago

#WCLC25 Highlights #CommunityOncology: 1. #FLAUR2 1L EGFR mNSCLC @dplanchard 2. #ACROSS2 1L EGFR mNSCLC @JordiRemon 3. #HARMONi 2L EGFR NSCLC 4. #ALCHEMIST Adj ALK+ NSCLC 5. #NadimAdjuvant Adj ChemoIO NSCLC #lcsm #OncTwitter @IASLC @DrJNaidoo @NReguart @IsaOpitz 1/6

OncBrothers's tweet photo. #WCLC25 Highlights #CommunityOncology:

1. #FLAUR2 1L EGFR mNSCLC @dplanchard

2. #ACROSS2 1L EGFR mNSCLC @JordiRemon

3. #HARMONi 2L EGFR NSCLC

4. #ALCHEMIST Adj ALK+ NSCLC

5. #NadimAdjuvant Adj ChemoIO NSCLC

#lcsm #OncTwitter @IASLC @DrJNaidoo @NReguart @IsaOpitz

1/6 https://t.co/FeRFrlax2c

2

139

60

88

16K

OncLive.com

@OncLive

9 months ago

Aumolertinib Plus Chemotherapy Improves PFS in EGFR-Mutated NSCLC #ACROSS2 #WCLC25 @IASLC #LCSM https://t.co/i5VzC8liK1

0

4

3

0

804

Eric K. Singhi, MD @lungoncdoc

9 months ago

The #ACROSS2 study raises an important (and somewhat surprising!!) question: Is a TP53 co-mutation alone really the high-risk feature we typically assume it is when deciding on treatment intensification for our patients with EGFR+ mNSCLC? #WCLC25 @IASLC

lungoncdoc's tweet photo. The #ACROSS2 study raises an important (and somewhat surprising!!) question: Is a TP53 co-mutation alone really the high-risk feature we typically assume it is when deciding on treatment intensification for our patients with EGFR+ mNSCLC? #WCLC25 @IASLC https://t.co/XUuE1nYiWD

3

29

11

9

3K

Dr. Estela Rodriguez

@Latinamd

9 months ago

✅Day1 of @IASLC #WCLC25 with a lot of new data to come out tomorrow morning at the Presidential Symposium on mgmt of Biomarker-driven lung cancer🫁: 🎯#FLAURA2 OS of Osimertinib +chemo in 1L EGFR 🎯#ACROSS2 Aumolertinib +chemo in 1L EGFR 🎯#HARMONI Ivonescimab + chemo post EGFR TKI 🎯#ARROS-1 Zidesamtinib post ROS1 TKI 🎯#ALCHEMIST Adjuvant Crizotinib for ALK+ 🫁 @EGFRResisters @ALKPositiveinc @ros1cancer